References:
1. Burkhardt B, Hermiston ML. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.Br J Haematol . 2019;185(6):1158-1170. doi:10.1111/bjh.15793
2. Soslow RA, Baergen RN, Warnke RA. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer . 1999;85(12):2648-2654.
3. Ducassou S, Ferlay C, Bergeron C, et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. Br J Haematol . 2011;152(4):441-451. doi:10.1111/j.1365-2141.2010.08541.x
4. Minard-Colin V, Brugières L, Reiter A, et al. Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. J ClinOncol Off J Am SocClinOncol . 2015;33(27):2963-2974. doi:10.1200/JCO.2014.59.5827
5. Schmidt E, Burkhardt B. Lymphoblastic lymphoma in childhood and adolescence. PediatrHematolOncol . 2013;30(6):484-508. doi:10.3109/08880018.2013.789574
6. Mussolin L, Buldini B, Lovisa F, et al. Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience. Pediatr Blood Cancer . 2015;62(11):1906-1913. doi:10.1002/pbc.25607
7. Nakatani K, Nakamoto Y, Watanabe K, Saga T, Higashi T, Togashi K. Roles and limitations of FDG PET in pediatric non-Hodgkin lymphoma.ClinNucl Med . 2012;37(7):656-662. doi:10.1097/RLU.0b013e318238f72b
8. Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.Blood . 2000;95(2):416-421.
9. Landmann E, Burkhardt B, Zimmermann M, et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica . 2017;102(12):2086-2096. doi:10.3324/haematol.2015.139162
10. Termuhlen AM, Smith LM, Perkins SL, et al. Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children’s Oncology Group trial A5971: a report from the Children’s Oncology Group. Pediatr Blood Cancer . 2012;59(7):1229-1233. doi:10.1002/pbc.24149
11. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol . 2005;131(1):39-49. doi:10.1111/j.1365-2141.2005.05735.x
12. Termuhlen AM, Smith LM, Perkins SL, et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children’s Oncology Group. Br J Haematol . 2013;162(6):792-801. doi:10.1111/bjh.12460
13. Sandlund JT, Pui C-H, Zhou Y, et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia . 2009;23(6):1127-1130. doi:10.1038/leu.2008.400
14. Uyttebroeck A, Suciu S, Laureys G, et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer OxfEngl 1990 . 2008;44(6):840-846. doi:10.1016/j.ejca.2008.02.011
15. Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group (POG 9404). Blood . 2011;118(4):874-883. doi:10.1182/blood-2010-06-292615
16. Gao Y-J, Pan C, Tang J-Y, et al. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001–2010. Pediatr Blood Cancer . 2014;61(4):659-663. doi:10.1002/pbc.24848
17. Nowell PC. The clonal evolution of tumor cell populations.Science . 1976;194(4260):23-28. doi:10.1126/science.959840
18. Rushton CK, Arthur SE, Alcaide M, et al. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.Blood Adv . 2020;4(13):2886-2898. doi:10.1182/bloodadvances.2020001696
19. Suryanarayan K, Shuster JJ, Donaldson SS, Hutchison RE, Murphy SB, Link MP. Treatment of Localized Primary Non-Hodgkin’s Lymphoma of Bone in Children: A Pediatric Oncology Group Study. J ClinOncol . 1999;17(2):456-456. doi:10.1200/JCO.1999.17.2.456
20. Lones MA, Perkins SL, Sposto R, et al. Non-Hodgkin’s lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children’s Cancer Group report. J ClinOncol Off J Am SocClinOncol . 2002;20(9):2293-2301. doi:10.1200/JCO.2002.06.017
21. Loeffler JS, Tarbell NJ, Kozakewich H, Cassady JR, Weinstein HJ. Primary lymphoma of bone in children: analysis of treatment results with adriamycin, prednisone, Oncovin (APO), and local radiation therapy.J ClinOncol Off J Am SocClinOncol . 1986;4(4):496-501. doi:10.1200/JCO.1986.4.4.496
22. Susnerwala SS, Dinshaw KA, Pande SC, et al. Primary lymphoma of bone: experience of 39 cases at the Tata Memorial Hospital, India.J SurgOncol . 1990;44(4):229-233. doi:10.1002/jso.2930440408
23. Gross TG, Hale GA, He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant . 2010;16(2):223-230. doi:10.1016/j.bbmt.2009.09.021
LEGENDS
TABLE 1. Clinical profile and Outcomes of pediatric B-Lymphoblastic Lymphoma
TABLE 2. Univariate analysis of prognostic variables affecting survival in pB-LBL
Figure 1. Modified BFM 90 Treatment Schema used in Study (*IT- Intrathecal, #CR-Complete response)
Figure 2. 5-year Event free survival is 80%
Figure 3. 5-year Overall survival is 91%